| ID | stock | broker | amount | AVG | BUY TOTAL | date | time | Filled price | amount filled | volume | Total filled | total Stock | Total $ | final price | Remark |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 53 | BIOL | TD | 40 | $25.85 | $1,033.97 | 9/2/2022 | $1.37 | 4,000.00 | 0 | $5,480.00 | 4040 | $6,513.97 | $1.61 |
Biolase gains after forecasting strong near-term outlook
BIOLASE (NASDAQ:BIOL) has climbed ~25.0% in the post-market after the company exceeded analyst expectations with its Q2 2021 financials and provided a solid outlook for the current quarter,
Second-quarter revenue has risen ~211% YoY to $9.1M, indicating an improvement of ~6% from the pre-pandemic level.
Net loss narrowed to $702K from $4.7M a year ago as gross margin expanded by 1,200bps from the previous year to ~44%. Meanwhile, the cash and equivalents stood at $37.1M, more than double the level at the end of 2020.
Q3 2021, the weakest quarter seasonally, is expected to generate the same level of revenue for the company as the second quarter of 2021, according to projections from Biolase (BIOL). However, the consensus Q3 2021 estimates for Biolase stands at $8.9M.
Now read: Biolase EPS beats by $0.04, beats on revenue
Stocks: Profile
No comments:
Post a Comment